EnteroMedics, a St. Paul, Minnesota company, announced the first commercial implantation of the Maestro vBloc Neurometabolic Therapy system in the U.S. The device was approved by the FDA earlier this year for for treatment of obesity, metabolic disorders, and other GI conditions.
vBloc technology, as the name implies, blocks signals originating in the stomach from reaching the brain via the vagus nerve. This prevents the patient feeling hunger pangs and will hopefully bring a sense of control to many on the front lines of the obesity epidemic.
The Maestro is approved for adults with a “BMI of 40 to 45 kg/m2 or a BMI of 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years,” according to EnteroMedics.
Here’s a company info video about the Maestro system:
Product page: Maestro System…